Comparative analysis of cardiovascular risk scores in patients with rheumatoid arthritis combined with thrombocytosis and normal platelet level


DOI: https://dx.doi.org/10.18565/therapy.2025.1.55-63

Melnikov E.S., Morozova K.P.

1) I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg; 2) V.A. Nasonova Clinical Rheumatology Hospital No. 25, Saint Petersburg
Abstract. Cardiovascular diseases are the main cause of mortality among patients with rheumatoid arthritis (RA). Until nowadays, cardiovascular risk assessment in patients with RA remains an actual and complex task.
The aim: to perform a comparative analysis of cardiovascular risk (CVR), biological and passport age in patients with RA, with thrombocytosis and normal platelet level.
Material and methods. 85 patients with RA (40 with thrombocytosis and 45 with normal platelet levels) were involved in the study. The average age of the participants was 50.3 ± 9.8 years. The total group included 54 (63.5%) female and 31 (36.5%) male patients. To assess the risk of cardiovascular diseases, the SCORE scales multiplied by a correction factor of 1.5 (mSCORE), RRS, QRISK3 and ASSIGN were used. Passport and biological age of the patient was determined using the QRISK3 scale.
Results. QRISK3 scale made it possible to establish a statistically significant increase in CVR in patients with RA and thrombocytosis comparatively to the group of patients with RA and normal platelet level (p = 0.021). The odds of developing high cardiovascular risk in patients with thrombocytosis were 2.78 times higher comparatively to the group of RA patients without thrombocytosis (95% confidence interval: 1.15–6.73). The use of other scales (mSCORE, RRS, ASSIGN) did not reveal statistically significant differences in high CVR in the compared groups.
Conclusion. QRISK3 scale is the most informative tool for assessing CVR in patients with RA, especially in the presence of thrombocytosis.
Keywords: QRISK3, thrombocytosis, rheumatoid arthritis, cardiovascular risk
Read entire article

Literature

1. Ребров А.П. Поражение сердца у больных с ревматоидным артритом. Южно-Российский журнал терапевтической практики. 2022; 3(1): 15–19. (Rebrov A.P. Heart damage in patients with rheumatoid arthritis. Yuzhno-Rossiyskiy zhurnal terapevticheskoy praktiki = South Russian Journal of Therapeutic Practice. 2022; 3(1): 15–19 (In Russ.)).


https://doi.org/10.21886/2712-8156-2022-3-1-15-19. EDN: EUSHFL.


2. Liao K.P. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2017; 27(2): 136–40.


https://doi.org/10.1016/j.tcm.2016.07.006. PMID: 27612551. PMCID: PMC5253086.


3. Dadoun S., Zeboulon-Ktorza N., Combescure C. et al. Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis. Joint Bone Spine. 2013; 80(1): 29–33.


https://doi.org/10.1016/j.jbspin.2012.02.005. PMID: 22459416.


4. Popescu D., Rezus E., Badescu M.C. et al. Cardiovascular risk assessment in rheumatoid arthritis: Accelerated atherosclerosis, new biomarkers, and the effects of biological therapy. Life (Basel). 2023; 13(2): 319.


https://doi.org/10.3390/life13020319. PMID: 36836675. PMCID: PMC9965162.


5. Agca R., Heslinga S.C., Rollefstad S. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017; 76(1): 17–28.


https://doi.org/10.1136/annrheumdis-2016-209775. PMID: 27697765.


6. Клиническая ревматология. Руководство для врачей. 3-е издание, переработанное и дополненное. Под ред. В.И. Мазурова. М.: Е-ното. 2021; 696 с. (Clinical rheumatology. Guide for doctors. 3rd edition, revised and enlarged. Ed. by Mazurov V.I. Moscow: E-noto. 2021; 696 pp. (In Russ.)). ISBN: 978-5-906023-26-1.


7. Герасимова Е.В., Попкова Т.В., Герасимова Д.А. с соавт. Применение шкал сердечно-сосудистого риска для идентификации атеросклероза сонных артерий у больных ревматоидным артритом. Терапевтический архив. 2021; 93(5): 561–567. (Gerasimova E.V., Popkova T.V., Gerasimova D.A. et al. Application of cardiovascular risk scales to identify carotid atherosclerosis in patients with rheumatoid arthritis. Terapevticheskiy arkhiv = Therapeutic Archive. 2021; 93(5): 561–567 (In Russ.)).


https://doi.org/10.26442/00403660.2021.05.200787. EDN: ZRVVAZ.


8. Арутюнов А.Г., Ноздрин А.В., Шавгулидзе К.Б. с соавт. Различия паспортного и биологического (фактического) возраста в популяции российских пациентов, страдающих артериальной гипертензией (анализ регистра «ГИПЕРИОН»). Терапевтический архив. 2018; 90(4): 21–28. (Arutyunov A.G., Nozdrin A.V., Shavgulidze K.B. et al. Ifferences between passport and biological (actual) age in the population of Russian patients suffering from arterial hypertension (analysis of the “HYPERION” register). Terapevticheskiy arkhiv = Therapeutic Archive. 2018; 90(4): 21–28 (In Russ.)).


https://doi.org/10.26442/terarkh201890421-28. EDN: WBXTXN.


9. Protogerou A.D., Panagiotakos D.B., Zampeli E. et al. Arterial hypertension assessed “out-of-office” in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated “white coat” phenomenon. Arthritis Res Ther. 2013; 15(5): R142.


https://doi.org/10.1186/ar4324. PMID: 24286134. PMCID: PMC3978881.


10. Anyfanti P., Gkaliagkousi E., Triantafyllou A. et al. Hypertension in rheumatic diseases: Prevalence, awareness, treatment, and control rates according to current hypertension guidelines. J Hum Hypertens. 2021; 35(5): 419–27.


https://doi.org/10.1038/s41371-020-0348-y. PMID: 32382031.


11. Panoulas V.F., Metsios G.S., Pace A.V. et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford). 2008; 47(9): 1286–98.


https://doi.org/10.1093/rheumatology/ken159. PMID: 18467370.


12. Nikiphorou E., de Lusignan S., Mallenet C.D. al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: A population-based study. Heart. 2020; 106(20): 1566–72.


https://doi.org/10.1136/heartjnl-2019-316193. PMID: 32209618. PMCID: PMC7525791.


13. Chen J., Norling L.V., Cooper D. Cardiac dysfunction in rheumatoid arthritis: The role of inflammation. Cells. 2021; 10(4): 881.


https://doi.org/10.3390/cells10040881. PMID: 33924323. PMCID: PMC8070480.


14. Bandyopadhyay D., Banerjee U., Hajra A. et al. Trends of cardiac complications in patients with rheumatoid arthritis: Analysis of the United States national inpatient sample; 2005–2014. Curr Probl Cardiol. 2021; 46(3): 100455.


https://doi.org/10.1016/j.cpcardiol.2019.100455. PMID: 31526517.


15. Black R.J., Lester S., Tieu J. et al. Mortality estimates and excess mortality in rheumatoid arthritis. Rheumatology (Oxford). 2023; 62(11): 3576–83.


https://doi.org/10.1093/rheumatology/kead106. PMID: 36919770. PMCID: PMC10629787.


16. van den Hoek J., Boshuizen H.C., Roorda L.D. et al. Mortality in patients with rheumatoid arthritis: A 15-year prospective cohort study. Rheumatology international. 2017; 37(4): 487–93.


https://doi.org/10.1093/rheumatology/kead106. PMID: 36919770. PMCID: PMC10629787.


17. Hoogendijk E.O., Deeg D.J.H., Poppelaars J. et al. The longitudinal aging study Amsterdam: Cohort update 2016 and major findings. Eur J Epidemiol. 2016; 31(9): 927–45.


https://doi.org/10.1007/s10654-016-0192-0. PMID: 27544533. PMCID: PMC5010587.


18. Hospers G.P., Smulders Y.M., Maier A.B. et al. Relation between blood pressure and mortality risk in an older population: Role of chronological and biological age. J Intern Med. 2015; 277(4): 488–97.


https://doi.org/10.1111/joim.12284. PMID: 25041041.


19. Muller M., Smulders Y.M., de Leeuw P.W., Stehouwer C.D.A. Treatment of hypertension in the oldest old: A critical role for frailty? Hypertension. 2014; 63(3): 433–41.


https://doi.org/10.1161/hypertensionaha.113.00911. PMID: 24324042.


20. Odden M.C., Peralta C.A., Haan M.N., Covinsky K.E. Rethinking the association of high blood pressure with mortality in elderly adults: The impact of frailty. Arch Intern Med. 2012; 172(15): 1162–68.


https://doi.org/10.1001/archin-ternmed.2012.2555. PMID: 22801930. PMCID: PMC3537835.


21. Sabayan B., van Vliet P., de Ruijter W. et al. High blood pressure, physical and cognitive function, and risk of stroke in the oldest old: The Leiden 85-plus Study. Stroke. 2013; 44(1): 15–20.


https://doi.org/10.1161/strokeaha.112.663062. PMID: 23132780.


About the Autors

Evgeniy S. Melnikov, MD, assistant at the Department of therapy, rheumatology, examination of temporary disability and quality of medical care with a course in hematology and transfusiology named after E.E. Eichwald of I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, rheumatologist at V.A. Nasonova Clinical Rheumatology Hospital No. 25. Address: 190068, Saint Petersburg, 30 Bol’shaya Pod’yacheskaya St.
E-mail: emelnikov@euat.ru
ORCID: https://orcid.org/0000-0002-8521-6542. eLibrary SPIN: 4544-0596
Kira P. Morozova, MD, postgraduate student of the Department of therapy, rheumatology, examination of temporary disability and quality of medical care with a course in hematology and transfusiology named after E.E. Eichwald of I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, rheumatologist at V.A. Nasonova Clinical Rheumatology Hospital No. 25. Address: 190068, Saint Petersburg, 30 Bol’shaya Pod’yacheskaya St.
E-mail: kiramorozoba@mail.ru
ORCID: https://orcid.org/0000-0002-4113-3104


Similar Articles

Back to Content

Бионика Медиа